List of works - Daniel B Costa

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

scientific article

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

scientific article published on 04 September 2012

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

scientific article

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.

scientific article

CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.

scientific article

Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.

scientific article published on 18 July 2011

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response

scientific article

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases

scientific article published on 26 January 2015

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.

scientific article published on July 2009

EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications

scientific article

Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer

scientific article

Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib

scientific article published on October 28, 2010

Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers.

scientific article

Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cells

scientific article published on 15 October 2006

The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non–Small Cell Lung Cancer with EGFR Mutations

scientific article published on June 25, 2012

Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers

scientific article published on 3 July 2007

A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia.

scientific article published in September 2007

Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations.

scientific article

Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.

scientific article

Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer

scientific article

Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer.

scientific article

Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer

scientific article published on 28 January 2014

Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches

scientific article

Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities

scientific article published on May 1, 2011

Management and Future Directions in Non-Small Cell Lung Cancer with Known Activating Mutations

scientific article published on January 1, 2014

Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer

scientific article published on 14 October 2013

In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer

scientific article

β-catenin contributes to lung tumor development induced by EGFR mutations

scientific article

Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells.

scientific article

Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation.

scientific article

Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice.

scientific article published on 07 August 2013

Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M.

scientific article

Adequacy of lymph node transbronchial needle aspirates using convex probe endobronchial ultrasound for multiple tumor genotyping techniques in non-small-cell lung cancer.

scientific article

Family history of lung cancer in never smokers with non-small-cell lung cancer and its association with tumors harboring EGFR mutations

scientific article published on December 27, 2012

Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung

scientific article

Improvement of Type 2 Diabetes in a Lung Cancer Patient Treated With Erlotinib

scientific article published on 01 July 2006

The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer

scientific article published on 04 March 2016

Experience with targeted next generation sequencing for the care of lung cancer: insights into promises and limitations of genomic oncology in day-to-day practice

scientific article

C/EBPα mutations in lung cancer

scientific article published on 12 June 2006

Molecular testing in lung cancer: the time is now.

scientific article published on September 2010

Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas.

scientific article published on 07 March 2016

Alterations of tumor microenvironment by carbon monoxide impedes lung cancer growth

scientific article published on 15 March 2016

ALK translocation in non-small cell lung cancer with adenocarcinoma and squamous cell carcinoma markers.

scientific article

Case of fatal sickle cell intrahepatic cholestasis despite use of exchange transfusion in an African-American patient.

scientific article published in July 2006

The Clinical Use of Genomic Profiling to Distinguish Intrapulmonary Metastases From Synchronous Primaries in Non-Small-Cell Lung Cancer: A Mini-Review

scientific article published on 26 March 2015

Lazarus-Type Response to Crizotinib in a Patient with Poor Performance Status and Advanced MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma

scientific article published on February 2016

Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling

scientific article

Acquired resistance to the ALK inhibitor crizotinib in the absence of an ALK mutation.

scientific article published in March 2012

A novel splicing mutation of the alpha-spectrin gene in the original hereditary pyropoikilocytosis kindred.

scientific article published on 8 September 2005

Identification and characterization of ALK kinase splicing isoforms in non-small-cell lung cancer.

scientific article

List of works by Daniel B Costa

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.

CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.

Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.

EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications

Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer

Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib

Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers.

Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cells

The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non–Small Cell Lung Cancer with EGFR Mutations

Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers

A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia.

Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations.

Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.

Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer

Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer.

Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer

Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches

Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities

Management and Future Directions in Non-Small Cell Lung Cancer with Known Activating Mutations

Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer

In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer

β-catenin contributes to lung tumor development induced by EGFR mutations

Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells.

Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation.

Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice.

Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M.

Adequacy of lymph node transbronchial needle aspirates using convex probe endobronchial ultrasound for multiple tumor genotyping techniques in non-small-cell lung cancer.

Family history of lung cancer in never smokers with non-small-cell lung cancer and its association with tumors harboring EGFR mutations

Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung

Improvement of Type 2 Diabetes in a Lung Cancer Patient Treated With Erlotinib

The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer

Experience with targeted next generation sequencing for the care of lung cancer: insights into promises and limitations of genomic oncology in day-to-day practice

C/EBPα mutations in lung cancer

Molecular testing in lung cancer: the time is now.

Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas.

Alterations of tumor microenvironment by carbon monoxide impedes lung cancer growth

ALK translocation in non-small cell lung cancer with adenocarcinoma and squamous cell carcinoma markers.

Case of fatal sickle cell intrahepatic cholestasis despite use of exchange transfusion in an African-American patient.

The Clinical Use of Genomic Profiling to Distinguish Intrapulmonary Metastases From Synchronous Primaries in Non-Small-Cell Lung Cancer: A Mini-Review

Lazarus-Type Response to Crizotinib in a Patient with Poor Performance Status and Advanced MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma

Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling

Acquired resistance to the ALK inhibitor crizotinib in the absence of an ALK mutation.

A novel splicing mutation of the alpha-spectrin gene in the original hereditary pyropoikilocytosis kindred.

Identification and characterization of ALK kinase splicing isoforms in non-small-cell lung cancer.